AtriCure, Inc. (ATRC) P/E Ratio History
ExpensiveTrading at 196.0x vs 5Y avg 91.9x · 100th percentile · Material premium to history · Data 2021–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, AtriCure, Inc. (ATRC) trades at a price-to-earnings ratio of 196.0x, with a stock price of $58.54 and trailing twelve-month earnings per share of $0.30.
The current P/E is 113% above its 5-year average of 91.9x. Over the past five years, ATRC's P/E has ranged from a low of 35.2x to a high of 187.7x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, ATRC trades at a 696% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, ATRC commands a significant premium over the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ATRC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ATRC Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ATRC P/E vs Peers
Cardiovascular, Renal & Blood Devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $191B | 40.6 | 4.91 | -51% | |
| $131B | 25.0 | 3.58 | +3% | |
| $64B | 17.8Lowest | - | +55% | |
| $665B | 42.0 | 2.82 | +91%Best | |
| $59B | 57.8 | 8.16 | -74% | |
| $125B | 34.6 | 2.33Best | +8% | |
| $20B | 26.3 | - | -20% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ATRC Historical P/E Data (2021–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $56.20 | $0.30 | 187.7x | +104% |
| FY2026 Q2 | - | $27.98 | $0.21 | 131.9x | +43% |
| FY2022 Q2 | - | $40.86 | $1.16 | 35.2x | -62% |
| FY2022 Q1 | - | $65.67 | $1.12 | 58.6x | -36% |
| FY2021 Q4 | Dec 31 2021 | $69.53 | $1.07 | 65.0x | -29% |
| FY2021 Q3 | - | $69.55 | $0.95 | 73.2x | -20% |
Average P/E for displayed period: 91.9x
ATRC Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ATRC — Frequently Asked Questions
Quick answers to the most common questions about buying ATRC stock.
What is ATRC's P/E ratio?
AtriCure, Inc. (ATRC) trailing twelve-month P/E ratio is 196.0x, based on TTM diluted EPS of $0.30. The 5-year average P/E is 91.9x and the historical range spans 35.2x to 187.7x.
Is ATRC stock overvalued or undervalued?
ATRC trades at 196.0x P/E, above its 5-year average of 91.9x. The 100th percentile ranking within the 35.2x–187.7x historical range indicates a premium to historical valuation.
Is ATRC stock expensive?
Yes, ATRC is expensive relative to its own history. The current P/E of 196.0x is above the 5-year average of 91.9x and also above the Healthcare sector median of 24.6x. The stock sits at the 100th percentile of its 5-year valuation range.
What is ATRC's historical P/E range?
Over the past 5 years, ATRC's P/E ratio has ranged from 35.2x to 187.7x, with a median of 73.2x and an average of 91.9x. The current P/E of 196.0x places the stock at the 100th percentile of this range. Full historical data spans 2021–2026.
How does ATRC's P/E compare to the S&P 500?
ATRC trades at 196.0x P/E versus the S&P 500 median of 21.8x. The 799% premium to the market typically reflects higher expected earnings growth or quality.
How does ATRC's valuation compare to Healthcare peers?
AtriCure, Inc. P/E of 196.0x compares to the Healthcare sector median of 24.6x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ATRC's PEG ratio?
ATRC PEG ratio is N/A, based on a P/E of 196.0x and EPS growth of 74.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ATRC's earnings yield?
ATRC earnings yield is 0.51%, the inverse of its 196.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.